Redmile Group

Bambusa Therapeutics operates as biotechnology company, that focuses on developing bispecific antibodies.

Abcuro, Inc. is a biotechnology company focused on developing immunotherapies for the treatment of autoimmunity and cancer. Established in 2015 and headquartered in Newton, Massachusetts, Abcuro specializes in creating therapeutic antibodies that target novel pathways in these diseases. The company employs advanced bioinformatics to analyze transcription data from human diseases, enabling them to identify new therapeutic targets within the immune system. By leveraging clinical insights and systematic target validation, Abcuro aims to develop immune-modulatory biotherapeutics that provide innovative treatment options for patients suffering from autoimmune disorders and cancer.

Atara Biotherapeutics, Inc. is a biotechnology company focused on developing off-the-shelf T-cell immunotherapies for patients with cancer, autoimmune diseases, and viral infections. The company is advancing tabelecleucel, a T-cell immunotherapy currently in Phase III clinical trials for treating Epstein-Barr virus-associated post-transplant lymphoproliferative disorder, as well as other related hematologic and solid tumors, including nasopharyngeal carcinoma. Atara is also working on next-generation CAR T immunotherapies targeting various indications, including ATA2271 and ATA3271 for mesothelin, and ATA2431 and ATA3219 for B-cell lymphomas. Additionally, its pipeline includes ATA188 for multiple sclerosis and several other candidates for conditions such as acute myeloid leukemia and cytomegalovirus. Founded in 2012, Atara Biotherapeutics is headquartered in South San Francisco, California, and collaborates with leading academic institutions to enhance its research and development efforts.

Clear Labs, Inc. is a food analytics company based in Menlo Park, California, founded in 2013. The company specializes in providing a comprehensive food analytics platform that utilizes next-generation sequencing and data analytics to enhance food safety and quality control. Its offerings include Clear Dx™ and Clear Safety™, which facilitate the rapid identification of pathogens and support public health initiatives. Clear Labs' platform delivers critical insights into the molecular composition of foods and ingredients, testing for authenticity, contaminants, allergens, and other safety parameters. By offering transparency across supply chains, the company serves food manufacturers, suppliers, and retailers, enabling them to improve operational efficiency and safety through detailed analytics and reporting.

RAPT Therapeutics is a clinical-stage biopharmaceutical company specializing in immunology. It is dedicated to discovering, developing, and commercializing oral small-molecule therapies aimed at addressing significant unmet medical needs in oncology and inflammatory diseases. The company employs a proprietary discovery and development engine to create highly selective small molecules that modulate immune responses related to these conditions. RAPT has advanced two notable drug candidates: FLX475, which targets the inhibition of immunosuppressive regulatory T cells in tumors, and RPT193, which selectively inhibits type 2 T helper cells in inflamed tissues. Both candidates have progressed to clinical trials within a short timeframe since the company's inception. Additionally, RAPT is exploring several other targets in the discovery phase, including general control nonderepressible 2 and hematopoietic progenitor kinase 1.

Scancell Holdings plc, established in 1997 and based in Oxford, UK, specializes in the discovery and development of novel vaccines for cancer treatment. The company's portfolio includes ImmunoBody and Moditope technology platforms, which harness the power of the immune system to target and destroy cancerous tumors. Its lead product, SCIB1, is in Phase II clinical trials for metastatic melanoma, while other candidates like SCIB2 and Modi-1 are in earlier stage trials for various solid tumors. Scancell has collaborations with BioNTech, ISA Pharmaceuticals, and academic institutions for vaccine development, including a COVID-19 vaccine project.

Neurogene Inc., established in 2018 and headquartered in New York, specializes in developing genetic medicines for treating neurological disorders. The company focuses on utilizing adeno-associated virus (AAV) vectors to deliver therapeutic genes for conditions such as Charcot-Marie Tooth disease type 4J (CMT4J), Aspartylglucosaminuria (AGU), and an undisclosed Lysosomal Storage Disease (LSD). Neurogene aims to provide effective treatment options where none currently exist, aiming to improve the quality of life for patients and families affected by these rare neurological disorders.

Candid Therapeutics is a biotechnology company specializing in the development of innovative therapies for immunological disorders. The company's primary focus is on creating novel, user-friendly treatments for autoimmune diseases. Their core technology involves advanced T-cell engager antibodies, which precisely redirect T-cells to selectively eliminate autoreactive B-cells, aiming to deliver transformative efficacy and improved therapeutic outcomes for patients.

Atara Biotherapeutics, Inc. is a biotechnology company focused on developing off-the-shelf T-cell immunotherapies for patients with cancer, autoimmune diseases, and viral infections. The company is advancing tabelecleucel, a T-cell immunotherapy currently in Phase III clinical trials for treating Epstein-Barr virus-associated post-transplant lymphoproliferative disorder, as well as other related hematologic and solid tumors, including nasopharyngeal carcinoma. Atara is also working on next-generation CAR T immunotherapies targeting various indications, including ATA2271 and ATA3271 for mesothelin, and ATA2431 and ATA3219 for B-cell lymphomas. Additionally, its pipeline includes ATA188 for multiple sclerosis and several other candidates for conditions such as acute myeloid leukemia and cytomegalovirus. Founded in 2012, Atara Biotherapeutics is headquartered in South San Francisco, California, and collaborates with leading academic institutions to enhance its research and development efforts.

Oruka Therapeutics is advancing innovative biologics to redefine patient care standards in chronic skin diseases.

GRO Biosciences is a biotechnology company focused on developing advanced protein therapeutics to address various health conditions, including diabetes, growth disorders, and autoimmunity. The company employs innovative technologies in computational protein design and synthetic biology, which enable it to create genomically recoded strains of bacteria capable of incorporating non-standard amino acids into proteins. This approach enhances the properties of the proteins, resulting in increased potency, stability, and targeted delivery. Through its technology platform, GRO Biosciences aims to provide improved treatment options across multiple disease classes, contributing to advancements in medical therapeutics.

Lycia Therapeutics operates as a biotechnology company focused on discovering and developing first-in-class therapeutics using its proprietary Lysosomal Targeting Chimeras (LYTACs) platform. This platform enables the degradation of extracellular and membrane-bound proteins associated with challenging-to-treat diseases like cancer and autoimmune disorders, aiming to provide effective treatments for patients.

Attovia Therapeutics is a biotherapeutics pipeline developer focused on immune-mediated illness and oncology. The company uses the nanobody platform to create tiny format binders with low picomolar affinity, increased selectivity, quicker internalization, and rapid tissue penetration, thereby assisting cancer patients' treatment.

Hansa Biopharma is a biopharmaceutical company focused on developing immunomodulatory treatments for individuals with rare immunological diseases. The company aims to create innovative therapies to address critical unmet medical needs in areas such as transplantation, autoimmune disorders, gene therapy, and oncology. Utilizing a proprietary antibody-cleaving enzyme technology platform, Hansa Biopharma targets pathogenic antibodies to enhance treatment outcomes. One of its key product candidates, imlifidase, is designed to facilitate kidney transplantation in sensitized patients and is also being explored for other organ and tissue transplantations, as well as acute autoimmune conditions. Operating primarily in Sweden, other European countries, and the United States, Hansa Biopharma generates the majority of its revenue from product sales.

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Encinitas, California, that specializes in developing innovative therapies for autoimmune diseases and inflammatory disorders. Incorporated in 2018, Ventyx focuses on creating selective inhibitors targeting TYK2, a key mediator in various inflammatory conditions. The company's clinical pipeline includes VTX958, an oral allosteric TYK2 inhibitor currently in Phase 1 trials, which aims to provide a safer alternative by avoiding the toxicities linked to broader Janus kinase inhibition. Additionally, Ventyx is advancing VTX002, a Phase 2-ready S1P1 receptor modulator intended for ulcerative colitis treatment, and VTX2735, a Phase 1 peripheral inhibitor of the NLRP3 inflammasome, which plays a significant role in multiple inflammatory diseases.

Cogent Biosciences is a biotechnology company dedicated to developing precision therapies for genetically defined diseases, aiming to treat the underlying causes and improve patient lives. The company employs proprietary T-cell engineering technology alongside tumor-targeting antibodies to harness the body's immune system against cancer. One of its key programs, CGT9486, is a selective tyrosine kinase inhibitor designed to inhibit specific mutations in KIT exon 17, which are associated with Systemic Mastocytosis and advanced gastrointestinal stromal tumors (GIST).

Sensorion SA is a biopharmaceutical company based in Montpellier, France, focused on developing innovative therapies for inner ear disorders, particularly hearing loss and vestibular deficits. Founded in 2009, the company is engaged in clinical-stage research, with key products including SENS-111, currently in phase II trials for acute unilateral vestibulopathy, and SENS-401, which is in phase I trials for sudden sensorineural hearing loss. Additionally, Sensorion is advancing SENS-300 in pre-clinical development for inner ear toxicity treatment. The company also collaborates with Cochlear Limited to explore combination therapies for cochlear implant patients, aiming to enhance therapeutic outcomes. Sensorion's commitment to addressing inner ear health positions it as a significant player in the biopharmaceutical landscape.

Silence Therapeutics plc is a biotechnology company based in London, specializing in the discovery and development of innovative RNA therapeutics. The company focuses on utilizing short interfering RNA (siRNA) technology to modulate gene expression and address various medical conditions, including hematology, cardiovascular diseases, and rare metabolic disorders. Its pipeline includes several product candidates, such as SLN124, aimed at treating iron overload disorders by silencing the TMPRSS6 gene, and SLN360, which targets the LPA gene to reduce the risk of cardiovascular diseases. Silence Therapeutics has established strategic collaborations with major organizations, including AstraZeneca, to advance the development of siRNA therapeutics across multiple disease areas. The company leverages its proprietary genetic toolkit and delivery systems to optimize therapeutic outcomes, harnessing the body's natural biological mechanisms for effective treatment.

AC Immune SA is a clinical-stage biopharmaceutical company based in Lausanne, Switzerland, specializing in the discovery, design, and development of therapeutic and diagnostic products aimed at neurodegenerative diseases linked to protein misfolding. Utilizing its proprietary technology platforms, the company creates vaccines, antibodies, and small molecules to target a range of neurodegenerative conditions. Its lead product candidate, crenezumab, is a humanized monoclonal antibody that is currently in a Phase II clinical trial for the prevention of Alzheimer's disease. Additionally, AC Immune is advancing other candidates, including ACI-24, an anti-Abeta vaccine in Phase II trials for Alzheimer's and Down syndrome, and ACI-35, an anti-Tau vaccine that has completed Phase Ib studies. The company also has ongoing research into Tau Morphomer aggregation inhibitors and various diagnostic tools targeting misfolded proteins. With a strong pipeline and collaborations with several prominent pharmaceutical companies and research institutions, AC Immune is positioned to make significant contributions to the field of neurodegenerative disease treatment.

Scancell Holdings plc, established in 1997 and based in Oxford, UK, specializes in the discovery and development of novel vaccines for cancer treatment. The company's portfolio includes ImmunoBody and Moditope technology platforms, which harness the power of the immune system to target and destroy cancerous tumors. Its lead product, SCIB1, is in Phase II clinical trials for metastatic melanoma, while other candidates like SCIB2 and Modi-1 are in earlier stage trials for various solid tumors. Scancell has collaborations with BioNTech, ISA Pharmaceuticals, and academic institutions for vaccine development, including a COVID-19 vaccine project.

AgomAb Therapeutics N.V., based in Gent, Belgium, specializes in the development of molecular therapies aimed at regenerating damaged tissues. The company focuses on creating agonistic monoclonal antibodies, known as agomAbs, which are designed to stimulate molecular and cellular repair mechanisms. These therapies have the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative diseases. AgomAb targets biologically validated pathways, including Transforming Growth Factor β and Hepatocyte Growth Factor, while employing specialized capabilities in organ-specific small molecules and high-affinity antibodies. The company boasts a diversified clinical pipeline addressing various fibrotic conditions and possesses comprehensive research and development expertise, alongside a strong track record in business development.

Star Therapeutics is a biotechnology company focused on developing innovative therapies for a wide range of rare diseases. The company aims to identify rare diseases that share common biological mechanisms, allowing it to create novel therapeutics capable of treating multiple conditions with a single treatment. This approach not only enhances the potential for effective solutions but also provides pharmaceutical companies with opportunities to address several rare diseases simultaneously. By targeting a diverse array of conditions, Star Therapeutics strives to significantly improve the lives of millions of patients affected by these challenging health issues.

Abcuro, Inc. is a biotechnology company focused on developing immunotherapies for the treatment of autoimmunity and cancer. Established in 2015 and headquartered in Newton, Massachusetts, Abcuro specializes in creating therapeutic antibodies that target novel pathways in these diseases. The company employs advanced bioinformatics to analyze transcription data from human diseases, enabling them to identify new therapeutic targets within the immune system. By leveraging clinical insights and systematic target validation, Abcuro aims to develop immune-modulatory biotherapeutics that provide innovative treatment options for patients suffering from autoimmune disorders and cancer.

ADARx Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on the research and development of RNA editing therapeutics. Established in 2019, the company specializes in genetic medicine by utilizing a proprietary platform that employs endogenous enzymes, specifically adenosine deaminase acting on RNA (ADAR), to precisely target and correct single point mutations in RNA transcripts. This innovative approach aims to restore the production of functional proteins, offering potential treatments for a variety of diseases, including those affecting genetic, cardiometabolic, complement-mediated, and central nervous system areas. ADARx Pharmaceuticals is dedicated to developing life-saving therapeutics that address genetic mutations and provide solutions for conditions that are currently considered incurable.

Sensorion SA is a biopharmaceutical company based in Montpellier, France, focused on developing innovative therapies for inner ear disorders, particularly hearing loss and vestibular deficits. Founded in 2009, the company is engaged in clinical-stage research, with key products including SENS-111, currently in phase II trials for acute unilateral vestibulopathy, and SENS-401, which is in phase I trials for sudden sensorineural hearing loss. Additionally, Sensorion is advancing SENS-300 in pre-clinical development for inner ear toxicity treatment. The company also collaborates with Cochlear Limited to explore combination therapies for cochlear implant patients, aiming to enhance therapeutic outcomes. Sensorion's commitment to addressing inner ear health positions it as a significant player in the biopharmaceutical landscape.

Immunome Inc., founded in 2006 and headquartered in Exton, Pennsylvania, is a biotechnology company focused on discovering, developing, and commercializing highly targeted and native human cancer antibodies against universal cancer antigens. The company utilizes its proprietary RealMAb technology to identify novel antigens and the corresponding native human antibodies that target them. Additionally, Immunome employs ScreenMab multiplex functional screening technology to pinpoint monoclonal antibodies with high specificity for tumor neoantigens.

ElevateBio, LLC is a holding company based in Cambridge, Massachusetts, founded in 2017. It focuses on developing cell and gene therapies for the treatment of cancer and viral infections. The company operates a portfolio of subsidiaries that aim to manufacture and commercialize innovative medicines. ElevateBio collaborates with leading scientists and inventors to create a robust portfolio of therapeutic solutions. Additionally, it has established a centralized facility designed to streamline the translation of cell and gene therapy research into viable medical products, ensuring that patients have access to treatments for severe diseases in a timely manner.

Krystal Biotech, Inc. is a biopharmaceutical company based in Pittsburgh, Pennsylvania, specializing in gene therapy for patients with rare skin diseases. Founded in 2015, the company develops innovative treatments using its proprietary STAR-D gene therapy platform, which targets dermatological conditions caused by genetic mutations. Its lead candidate, beremagene geperpavec (B-VEC), is in clinical development for dystrophic epidermolysis bullosa, having completed Phase I/II studies. Krystal Biotech is also advancing other product candidates, including KB105, which is in Phase I/II trials for autosomal recessive congenital ichthyosis, and KB301 and KB104, which are in preclinical stages for aesthetic skin conditions and Netherton Syndrome, respectively. Additionally, the company is exploring treatments for chronic skin diseases through its discovery-stage candidate KB5xx. Krystal Biotech aims to enhance the quality of life for patients suffering from debilitating skin disorders with its gene therapy solutions.

Boundless Bio, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, focused on developing innovative therapies for the treatment of aggressive cancers. The company specializes in targeting extrachromosomal DNA (ecDNA), a key factor in the amplification of oncogenes that affects over 14% of cancer patients. By investigating the biology of ecDNA, Boundless Bio aims to create transformative treatments for previously untreatable cancers. Its lead therapeutic candidate, BBI-355, is an oral selective inhibitor of checkpoint kinase 1 (CHK1) designed to manage the replication and transcription of ecDNA in cancer cells. Founded in 2018, Boundless Bio is committed to addressing the significant unmet medical needs of patients with oncogene amplified tumors.

Orbital Therapeutics is a biotechnology company dedicated to advancing global health through innovative RNA-based medicines. It develops a proprietary platform that combines cutting-edge RNA technology, delivery techniques, data analytics, and automation to create an extensive portfolio of transformative therapies across various disease areas such as vaccines, immunomodulation, protein replacement, and regenerative medicine. The company's mission is to provide patients with novel treatment options for diseases previously considered untreatable or challenging to manage.

Escient Pharmaceuticals, Inc. is a biotechnology company based in San Diego, California, specializing in the development and manufacture of G protein-coupled receptor (GPCR)-targeted drugs aimed at treating neuro-immuno-inflammatory and autoreactive diseases. Founded in 2017, Escient focuses on harnessing the therapeutic potential of specific orphan GPCRs, particularly the Mas-Related G-Protein Receptors (Mrgprs). The company aims to provide innovative therapies for a variety of conditions, including mast cell-mediated disorders and cholestatic pruritus, thereby expanding treatment options for healthcare providers facing these complex diseases.

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Encinitas, California, that specializes in developing innovative therapies for autoimmune diseases and inflammatory disorders. Incorporated in 2018, Ventyx focuses on creating selective inhibitors targeting TYK2, a key mediator in various inflammatory conditions. The company's clinical pipeline includes VTX958, an oral allosteric TYK2 inhibitor currently in Phase 1 trials, which aims to provide a safer alternative by avoiding the toxicities linked to broader Janus kinase inhibition. Additionally, Ventyx is advancing VTX002, a Phase 2-ready S1P1 receptor modulator intended for ulcerative colitis treatment, and VTX2735, a Phase 1 peripheral inhibitor of the NLRP3 inflammasome, which plays a significant role in multiple inflammatory diseases.

Kymera Therapeutics, Inc. is a biopharmaceutical company based in Watertown, Massachusetts, specializing in targeted protein degradation. Founded in 2015, the company employs a proprietary platform that utilizes the body's natural protein degradation system to selectively degrade disease-causing proteins. Kymera is advancing several therapeutic programs, including its IRAK4 program aimed at treating immunology-inflammation diseases such as hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis. Additionally, it is developing the IRAKIMiD program for MYD88-mutated diffuse large B cell lymphoma and the STAT3 program targeting hematologic malignancies, solid tumors, and autoimmune diseases. By focusing on previously untreatable conditions and using innovative small molecule modalities, Kymera Therapeutics aims to revolutionize drug discovery and create effective treatments for challenging diseases.

AlloVir, Inc. is a clinical-stage cell therapy company based in Cambridge, Massachusetts, specializing in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies aimed at preventing and treating serious viral-associated diseases. The company's lead product, Viralym-M, targets multiple viruses including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. Additionally, AlloVir is advancing several product candidates through preclinical and clinical stages, such as ALVR106 for respiratory syncytial virus and influenza, ALVR109 for SARS-CoV-2, ALVR107 for hepatitis B, and ALVR108 for human herpesvirus-8. The company, originally founded in 2013 as ViraCyte, Inc., rebranded to AlloVir in May 2019 and is committed to addressing the urgent medical needs of patients with limited treatment options for viral diseases.

Annexon Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapies for patients with classical complement-mediated disorders affecting the body, brain, and eye. The company's pipeline is built on a platform technology that targets well-researched autoimmune and neurodegenerative disease processes triggered by the aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon's lead product candidate, ANX005, is a full-length monoclonal antibody designed for intravenous administration to treat autoimmune and neurodegenerative disorders. Another key candidate, ANX007, is a monoclonal antibody Fab formulated for intravitreal administration to address neurodegenerative ophthalmic disorders. The company employs a biomarker-driven development strategy to ensure that its product candidates effectively engage the target at therapeutic doses within the intended patient tissue, while also exploring additional orphan and large market indications.

Scholar Rock, Inc. is a biotechnology company based in Cambridge, Massachusetts, specializing in the discovery and development of biologic therapies that selectively target dysregulated growth factors within disease microenvironments. The company's innovative approach focuses on modulating supracellular activation to address serious diseases, including fibrosis, musculoskeletal disorders, immuno-oncology, and autoimmune diseases. Scholar Rock's lead product candidate, SRK-015, is a first-in-class inhibitor designed to target the activation of the growth factor myostatin in skeletal muscle, specifically for the treatment of spinal muscular atrophy. The company is advancing this candidate through clinical development while also leveraging its proprietary platform to create a pipeline of additional product candidates aimed at transforming treatment for various serious conditions, including other neuromuscular disorders, cancer, and anemia.

RAPT Therapeutics is a clinical-stage biopharmaceutical company specializing in immunology. It is dedicated to discovering, developing, and commercializing oral small-molecule therapies aimed at addressing significant unmet medical needs in oncology and inflammatory diseases. The company employs a proprietary discovery and development engine to create highly selective small molecules that modulate immune responses related to these conditions. RAPT has advanced two notable drug candidates: FLX475, which targets the inhibition of immunosuppressive regulatory T cells in tumors, and RPT193, which selectively inhibits type 2 T helper cells in inflamed tissues. Both candidates have progressed to clinical trials within a short timeframe since the company's inception. Additionally, RAPT is exploring several other targets in the discovery phase, including general control nonderepressible 2 and hematopoietic progenitor kinase 1.

Neuron23, Inc. is a biotechnology company focused on developing and manufacturing innovative medicines for genetic disorders, particularly targeting neurological and immunological diseases. Founded in 2018 and headquartered in South San Francisco, California, with an additional office in Munich, Germany, the company utilizes advanced artificial intelligence technology and cutting-edge genetic research to enhance drug discovery. Neuron23 aims to create effective treatments for conditions such as Parkinson's disease and Alzheimer's disease, leveraging its AI-enabled platforms to identify and develop therapeutics that address the needs of patients suffering from these debilitating disorders.

Star Therapeutics is a biotechnology company focused on developing innovative therapies for a wide range of rare diseases. The company aims to identify rare diseases that share common biological mechanisms, allowing it to create novel therapeutics capable of treating multiple conditions with a single treatment. This approach not only enhances the potential for effective solutions but also provides pharmaceutical companies with opportunities to address several rare diseases simultaneously. By targeting a diverse array of conditions, Star Therapeutics strives to significantly improve the lives of millions of patients affected by these challenging health issues.

Electra Therapeutics is a clinical stage biotechnology company focused on developing therapies aimed at treating immunological diseases and cancer. The company specializes in targeting signal regulatory proteins (SIRP) to deplete pathological immune cells. Its lead product candidate, ELA026, is a monoclonal antibody currently in clinical development for secondary hemophagocytic lymphohistiocytosis (sHLH), a severe hyperinflammatory condition with no existing approved treatments. In addition to ELA026, Electra has two preclinical programs under development, highlighting its commitment to addressing unmet medical needs in the field of immunology and oncology.

Home Biosciences is a European venture builder focused on the biotechnology sector. The company is designed to facilitate scientific breakthroughs through its asset-centric operating model. By providing funding and operational support, Home Biosciences allows project teams to concentrate fully on their research and development efforts. This approach enables the creation of sustainable biotech ventures by assembling the necessary expertise and organizational structure, thereby fostering innovation and growth in the industry.

GRO Biosciences is a biotechnology company focused on developing advanced protein therapeutics to address various health conditions, including diabetes, growth disorders, and autoimmunity. The company employs innovative technologies in computational protein design and synthetic biology, which enable it to create genomically recoded strains of bacteria capable of incorporating non-standard amino acids into proteins. This approach enhances the properties of the proteins, resulting in increased potency, stability, and targeted delivery. Through its technology platform, GRO Biosciences aims to provide improved treatment options across multiple disease classes, contributing to advancements in medical therapeutics.

Sphere Fluidics Limited is a life sciences company focused on developing innovative technologies for single-cell analysis and characterization. The company offers unique products and collaborative research and development services that aid in the discovery of new cell strains and molecules. Its cell analysis systems facilitate the screening and isolation of rare and valuable biological variants, catering to various applications in research, therapeutic development, bioproduction, and diagnostics. By streamlining these processes, Sphere Fluidics enables clients to reduce costs and time, thereby accelerating advancements in biological and biopharmaceutical discovery.

Science 37, Inc. is a technology-enabled clinical trial company that specializes in developing patient-centric models for clinical research, aimed at accelerating biomedical discovery. The company utilizes its innovative platform, NORA (Network Oriented Research Assistant), a cloud-based mobile research tool that facilitates communication between researchers, patients, and mobile nurses through videos, surveys, and photographs. By providing decentralized clinical trial services, Science 37 enables access to diverse patient populations that traditional site-based research may overlook. The company has established itself as a leader in conducting virtual trials, leveraging an extensive network of telemedicine investigators and home-health nurses to enhance patient enrollment and retention. Serving a wide range of clients, including pharmaceutical sponsors, biotech firms, and academic institutions, Science 37 aims to transform clinical research through its comprehensive, fully integrated trial platform. Founded in 2014 and headquartered in Los Angeles, California, Science 37 continues to innovate in the field of clinical research.

Gritstone bio is a biotechnology company focused on developing immunotherapies for cancer and infectious diseases. The company initially concentrated on tumor-specific neoantigens but has expanded its programs to include viral antigens found on the surface of infected cells. Gritstone bio's approach leverages the body's natural immune system recognition of targets on abnormal cells, which is applicable to both anti-tumor and anti-viral immunity. Their pipeline includes several product candidates for treating solid tumors, such as GRANITE, SLATE, and CORAL. The company operates in a field that has seen significant advancements with the development and commercialization of immunotherapy drugs like checkpoint inhibitors, transforming cancer treatment.

Lycia Therapeutics operates as a biotechnology company focused on discovering and developing first-in-class therapeutics using its proprietary Lysosomal Targeting Chimeras (LYTACs) platform. This platform enables the degradation of extracellular and membrane-bound proteins associated with challenging-to-treat diseases like cancer and autoimmune disorders, aiming to provide effective treatments for patients.

Mammoth Biosciences, Inc. is a biotechnology company based in South San Francisco, California, founded in 2017 by CRISPR pioneer Jennifer Doudna and other key innovators. The company specializes in developing advanced CRISPR technologies, including its proprietary DETECTR platform, which enables the rapid detection of specific nucleic acids associated with various diseases. This platform facilitates diagnostic applications such as cancer screening, bacterial infections, and viral infections, allowing for real-time and simultaneous testing of multiple conditions. In addition to diagnostics, Mammoth Biosciences works on genome editing solutions for therapeutic purposes, targeting areas such as immuno-oncology, autoimmune diseases, and liver disorders. The company aims to democratize disease detection and enhance life science research through innovative, affordable, and efficient tools, while also leveraging its exclusive licensing of various Cas proteins for improved diagnostics and therapeutic applications.

Attralus, Inc. is a biopharmaceutical company dedicated to addressing the systemic nature of amyloidosis and enhancing the quality of life for affected patients. Incorporated in 2010 and headquartered in South San Francisco, California, Attralus develops proprietary peptide-based pan-amyloid targeting agents aimed at diagnosing and treating various forms and stages of systemic amyloidosis. Its product pipeline includes AT-01, a polybasic peptide radiotracer for diagnostic and monitoring purposes; AT-02, a peptide-immunoglobulin fusion for therapeutic use; and AT-03, an Fc-fusion protein designed for therapeutic applications. By targeting the common pathology present in all systemic amyloidosis diseases, Attralus seeks to create effective treatments for all subtypes, particularly those that currently lack available treatment options. The company was previously known as Aurora Bio, Inc., before rebranding in August 2020.

Zentera Therapeutics is a biopharmaceutical company.

Prime Medicine is a biotechnology company focused on developing genetic therapies using its innovative Prime Editing technology. This next-generation gene editing method allows for precise "search and replace" modifications in the genome, aimed at restoring normal genetic function. The company targets a wide range of diseases with significant unmet medical needs, leveraging the efficiency and versatility of its gene editing capabilities to address the underlying causes of these conditions. Through its commitment to advancing gene editing, Prime Medicine seeks to transform the landscape of genetic medicine.

Strand Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, that specializes in genetically programming mRNA to deliver innovative therapies aimed at enhancing patient outcomes. Founded in 2017, the company develops mRNA programming technology that allows for precise control over the location, timing, and intensity of therapeutic protein expression within the body. By employing mRNA-encoded logic circuits, Strand Therapeutics can achieve cell-type specific expression by detecting unique miRNA signatures and modulating protein dosage in response to externally administered small molecules. The company focuses on creating gene therapies powered by synthetic biology, including immunotherapies designed to enable cells to produce target cancer-killing proteins, thereby strengthening the body's immune response against cancer.

Mnemo Therapeutics is a biotechnology company focused on developing immune-based therapies, particularly cell therapies, aimed at providing accessible cures for solid tumors and blood cancers. The company's EnfiniT platform serves as an advanced drug discovery engine that harnesses a specific class of antigens along with various technologies to target tumorous epitopes found across multiple cancer types. By utilizing epigenetic variation and precision genetic engineering technologies, Mnemo Therapeutics creates allogeneic treatments designed to effectively address and overcome these diseases, advancing the field of cancer treatment.

RayzeBio, Inc. is a biotechnology company based in San Diego, California, founded in 2020. The company specializes in developing tumor-targeted small molecule medicines that leverage radioisotopes to improve cancer treatment outcomes. RayzeBio focuses on creating innovative radiopharmaceuticals, particularly utilizing alpha-emitting radioisotopes like Actinium-225, to target solid tumors effectively. With a robust pipeline of drug candidates, RayzeBio is committed to addressing significant market opportunities in oncology through late-stage clinical programs, development initiatives, and discovery efforts. The company's mission is to provide effective therapeutic solutions aimed at defeating cancer.

Quantum-Si is focused on revolutionizing the growing field of proteomics. The company’s suite of technologies are powered by a first-of-its-kind semiconductor chip designed to enable single-molecule next-generation protein sequencing and genomics, and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing.

Clear Labs, Inc. is a food analytics company based in Menlo Park, California, founded in 2013. The company specializes in providing a comprehensive food analytics platform that utilizes next-generation sequencing and data analytics to enhance food safety and quality control. Its offerings include Clear Dx™ and Clear Safety™, which facilitate the rapid identification of pathogens and support public health initiatives. Clear Labs' platform delivers critical insights into the molecular composition of foods and ingredients, testing for authenticity, contaminants, allergens, and other safety parameters. By offering transparency across supply chains, the company serves food manufacturers, suppliers, and retailers, enabling them to improve operational efficiency and safety through detailed analytics and reporting.

Boundless Bio, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, focused on developing innovative therapies for the treatment of aggressive cancers. The company specializes in targeting extrachromosomal DNA (ecDNA), a key factor in the amplification of oncogenes that affects over 14% of cancer patients. By investigating the biology of ecDNA, Boundless Bio aims to create transformative treatments for previously untreatable cancers. Its lead therapeutic candidate, BBI-355, is an oral selective inhibitor of checkpoint kinase 1 (CHK1) designed to manage the replication and transcription of ecDNA in cancer cells. Founded in 2018, Boundless Bio is committed to addressing the significant unmet medical needs of patients with oncogene amplified tumors.

Invivyd is a commercial-stage biopharmaceutical company dedicated to developing and commercializing antibody-based therapies aimed at protecting individuals from serious viral infectious diseases, particularly those with pandemic potential. The company focuses on innovative solutions that surpass the natural limits of immunity, starting with its lead product candidates for SARS-CoV-2. Notable among these candidates are ADG20, designed for the treatment and prevention of COVID-19, and VYD222, a monoclonal antibody optimized for enhanced potency and durability of protection. Invivyd's mission centers on delivering effective, long-lasting therapies to safeguard vulnerable populations from the severe repercussions of ongoing viral threats.

OncoResponse Inc. is an immuno-oncology biotechnology company based in Houston, Texas, focused on developing innovative cancer therapies. The company utilizes a proprietary human antibody platform to identify fully human monoclonal antibodies targeting immuno-oncology pathways. By probing the adaptive immune systems of cancer patients who have shown exceptional responses to checkpoint inhibitors, OncoResponse aims to discover novel therapeutic antibodies. Its research emphasizes addressing immunosuppressive myeloid biology and enhancing immune activation, with the goal of transforming cold tumors into hot tumors that are more responsive to treatment. Through its advanced antibody pipeline, OncoResponse is dedicated to providing effective solutions for cancer treatment.

Entrada Therapeutics, Inc. is a clinical-stage biotechnology company based in Boston, Massachusetts, focused on treating diseases through the intracellular delivery of biologics. Founded in 2016, the company has developed innovative technologies that facilitate the efficient delivery of proteins, peptides, and nucleic acids, targeting intracellular sites that have traditionally been difficult to access. Entrada's approach includes Intracellular Enzyme Replacement Therapy (IC-ERT) and Endosomal Escape Vehicle (EEV) therapeutics, which aim to improve the therapeutic index by enabling the delivery of a wide range of therapeutics across various organs and tissues. The company's pipeline addresses conditions related to neuromuscular diseases and expands into additional therapeutic areas, positioning Entrada at the forefront of advancing treatment options for patients with devastating illnesses.

Absci is a drug and target discovery company that leverages deep learning AI and synthetic biology to enhance the therapeutic potential of proteins. Its Integrated Drug Creation Platform streamlines the process of identifying novel drug targets, discovering optimal biotherapeutic candidates, and generating the necessary cell lines for manufacturing. By combining biologic drug discovery and cell line development into a single, efficient workflow, Absci collaborates with biotech and pharmaceutical innovators to develop next-generation protein-based drugs. These innovations include Bionic Proteins, which feature nonstandard amino acids, and other unique drug designs that may be unattainable through conventional methods. Absci's mission is to facilitate the development of improved medicines by effectively translating innovative ideas into viable drugs.

ElevateBio, LLC is a holding company based in Cambridge, Massachusetts, founded in 2017. It focuses on developing cell and gene therapies for the treatment of cancer and viral infections. The company operates a portfolio of subsidiaries that aim to manufacture and commercialize innovative medicines. ElevateBio collaborates with leading scientists and inventors to create a robust portfolio of therapeutic solutions. Additionally, it has established a centralized facility designed to streamline the translation of cell and gene therapy research into viable medical products, ensuring that patients have access to treatments for severe diseases in a timely manner.

AgomAb Therapeutics N.V., based in Gent, Belgium, specializes in the development of molecular therapies aimed at regenerating damaged tissues. The company focuses on creating agonistic monoclonal antibodies, known as agomAbs, which are designed to stimulate molecular and cellular repair mechanisms. These therapies have the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative diseases. AgomAb targets biologically validated pathways, including Transforming Growth Factor β and Hepatocyte Growth Factor, while employing specialized capabilities in organ-specific small molecules and high-affinity antibodies. The company boasts a diversified clinical pipeline addressing various fibrotic conditions and possesses comprehensive research and development expertise, alongside a strong track record in business development.

Amunix Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to discovering and developing innovative protein and peptide therapeutics aimed at treating cancer. The company employs several proprietary platforms, including XTEN for extending drug half-life, XPAT for analyzing protease activity in the tumor microenvironment, and ProTIA, which focuses on immuno-oncology therapeutics. Amunix's product pipeline includes prodrugs and transformative T-cell engagers designed to activate the immune system against solid tumors. The company collaborates with various academic, biotechnology, and pharmaceutical sectors, maintaining strategic partnerships with organizations such as Janssen and Biogen-Idec. Founded in 2006 and headquartered in Mountain View, California, Amunix strives to deliver breakthroughs that can harness the immune system to combat cancer more effectively.

Ayala Pharmaceuticals is a clinical-stage biopharmaceutical company based in Rehovot, Israel, founded in 2017. The company specializes in developing small molecule therapeutics for rare and aggressive cancers, focusing on genetically defined patient populations. Its lead product candidate is AL101, an intravenous gamma secretase inhibitor currently in Phase II clinical trials for treating recurrent/metastatic adenoid cystic carcinoma in patients with Notch-activating mutations. Additionally, Ayala Pharmaceuticals is developing AL102, an oral gamma secretase inhibitor in Phase I clinical trials for desmoid tumors. The company has a collaboration agreement with Novartis to develop AL102 for multiple myeloma. Ayala's approach involves using bioinformatics and next-generation sequencing to identify and address tumorigenic drivers of cancer, aiming to deliver targeted therapies to underserved patient populations.

Evox Therapeutics Limited is a biotechnology company based in Oxford, United Kingdom, that specializes in developing exosome-based therapeutics for the treatment of severe diseases with limited treatment options. Founded in 2016, the company focuses on harnessing and engineering extracellular vesicles, known as exosomes, to facilitate targeted delivery of nucleic acids and proteins. Evox's innovative platform allows for the modification of exosomes using advanced molecular engineering techniques, enabling effective drug delivery to specific organs, including the brain and central nervous system. By leveraging these natural delivery capabilities, Evox aims to overcome the limitations associated with conventional protein, antibody, and nucleic acid therapies, thereby creating novel therapeutic solutions that could significantly impact human health. The company is supported by a robust intellectual property portfolio and is positioned as a leader in this emerging therapeutic space.

Excision BioTherapeutics Inc. is a life science company based in Philadelphia, Pennsylvania, established in 2015. The company is dedicated to the development and commercialization of gene editing therapeutics aimed at treating life-threatening diseases caused by neurotropic viruses. Utilizing CRISPR-based technology, Excision BioTherapeutics focuses on creating advanced gene-editing medicines that can eradicate or disrupt viral genes in human patients. The company's mission is to advance these therapeutics into safe and effective treatments, significantly improving the lives of individuals affected by viral infections globally.

Beam Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, specializing in the development of precision genetic medicines utilizing its innovative base editing technology. Founded in 2017, the company aims to provide lifelong cures for patients suffering from serious diseases by targeting specific bases in the genome without inducing double-stranded breaks in DNA. Beam Therapeutics is actively developing therapies for a range of conditions, including sickle cell disease, beta-thalassemia, pediatric T-cell acute lymphoblastic leukemia, pediatric acute myeloid leukemia, alpha-1 antitrypsin deficiency, glycogen storage disorder type 1A, as well as ocular and central nervous system disorders. The company’s diverse pipeline includes several programs such as BEAM-101, BEAM-201, BEAM-301, BEAM-302, and ESCAPE, reflecting its commitment to advancing gene correction, gene modification, gene activation, gene silencing, and multiplex editing technologies.

Gritstone bio is a biotechnology company focused on developing immunotherapies for cancer and infectious diseases. The company initially concentrated on tumor-specific neoantigens but has expanded its programs to include viral antigens found on the surface of infected cells. Gritstone bio's approach leverages the body's natural immune system recognition of targets on abnormal cells, which is applicable to both anti-tumor and anti-viral immunity. Their pipeline includes several product candidates for treating solid tumors, such as GRANITE, SLATE, and CORAL. The company operates in a field that has seen significant advancements with the development and commercialization of immunotherapy drugs like checkpoint inhibitors, transforming cancer treatment.

SomaLogic, Inc. is a commercial-stage company based in Boulder, Colorado, specializing in protein biomarker discovery and clinical diagnostics. Founded in 1999, the company has developed advanced technologies such as SOMAmers, slow off-rate modified aptamers that specifically bind to target proteins, and the SOMAscan platform, which facilitates comprehensive protein measurement. This innovative approach allows for the analysis of protein biomarker signatures, significantly enhancing the understanding of health and disease beyond traditional genomic methods. SomaLogic's products are utilized in a variety of applications, including diagnostics for conditions in oncology, neurology, and cardiovascular and metabolic diseases, as well as in drug discovery and development. The company also offers diagnostic tests and protein measurement solutions for life science and biopharma researchers, contributing to advancements in medical science.

Neurogene Inc., established in 2018 and headquartered in New York, specializes in developing genetic medicines for treating neurological disorders. The company focuses on utilizing adeno-associated virus (AAV) vectors to deliver therapeutic genes for conditions such as Charcot-Marie Tooth disease type 4J (CMT4J), Aspartylglucosaminuria (AGU), and an undisclosed Lysosomal Storage Disease (LSD). Neurogene aims to provide effective treatment options where none currently exist, aiming to improve the quality of life for patients and families affected by these rare neurological disorders.

Neuron23, Inc. is a biotechnology company focused on developing and manufacturing innovative medicines for genetic disorders, particularly targeting neurological and immunological diseases. Founded in 2018 and headquartered in South San Francisco, California, with an additional office in Munich, Germany, the company utilizes advanced artificial intelligence technology and cutting-edge genetic research to enhance drug discovery. Neuron23 aims to create effective treatments for conditions such as Parkinson's disease and Alzheimer's disease, leveraging its AI-enabled platforms to identify and develop therapeutics that address the needs of patients suffering from these debilitating disorders.

RayzeBio, Inc. is a biotechnology company based in San Diego, California, founded in 2020. The company specializes in developing tumor-targeted small molecule medicines that leverage radioisotopes to improve cancer treatment outcomes. RayzeBio focuses on creating innovative radiopharmaceuticals, particularly utilizing alpha-emitting radioisotopes like Actinium-225, to target solid tumors effectively. With a robust pipeline of drug candidates, RayzeBio is committed to addressing significant market opportunities in oncology through late-stage clinical programs, development initiatives, and discovery efforts. The company's mission is to provide effective therapeutic solutions aimed at defeating cancer.

Achilles Therapeutics Ltd. is a biopharmaceutical company based in London, United Kingdom, specializing in the development of patient-specific immunotherapies designed to combat cancer. Founded in 2016, the company focuses on personalized vaccines and T cell therapies that utilize the body's immune system to target and eliminate cancer cells. Achilles Therapeutics aims to identify and target truncal tumor neoantigens and other markers present on cancer cells, allowing for precise attacks on tumors while sparing healthy tissue. The company is currently conducting clinical trials, including the CHIRON trial for non-small-cell lung cancer and the THETIS trial for recurrent or metastatic melanoma, to evaluate the efficacy and safety of its innovative therapies.

Mammoth Biosciences, Inc. is a biotechnology company based in South San Francisco, California, founded in 2017 by CRISPR pioneer Jennifer Doudna and other key innovators. The company specializes in developing advanced CRISPR technologies, including its proprietary DETECTR platform, which enables the rapid detection of specific nucleic acids associated with various diseases. This platform facilitates diagnostic applications such as cancer screening, bacterial infections, and viral infections, allowing for real-time and simultaneous testing of multiple conditions. In addition to diagnostics, Mammoth Biosciences works on genome editing solutions for therapeutic purposes, targeting areas such as immuno-oncology, autoimmune diseases, and liver disorders. The company aims to democratize disease detection and enhance life science research through innovative, affordable, and efficient tools, while also leveraging its exclusive licensing of various Cas proteins for improved diagnostics and therapeutic applications.

Nuvation Bio Inc. is a biopharmaceutical company dedicated to addressing unmet needs in oncology through the development of novel therapies for challenging cancers. Founded in 2018 and headquartered in New York, with an additional office in San Francisco, Nuvation Bio focuses on treating patients whose conditions have not responded to conventional treatments. The company's leading clinical-stage candidate, NUV-868, is a BD2-selective oral small molecule BET inhibitor that targets the BRD4 protein, which plays a crucial role in regulating tumor growth and differentiation. In addition to NUV-868, Nuvation Bio is advancing a proprietary small molecule Drug-Drug Conjugate platform aimed at enhancing therapeutic efficacy. The company’s comprehensive portfolio includes multiple drug development candidates designed to meet the specific needs of cancer patients.

Absci is a drug and target discovery company that leverages deep learning AI and synthetic biology to enhance the therapeutic potential of proteins. Its Integrated Drug Creation Platform streamlines the process of identifying novel drug targets, discovering optimal biotherapeutic candidates, and generating the necessary cell lines for manufacturing. By combining biologic drug discovery and cell line development into a single, efficient workflow, Absci collaborates with biotech and pharmaceutical innovators to develop next-generation protein-based drugs. These innovations include Bionic Proteins, which feature nonstandard amino acids, and other unique drug designs that may be unattainable through conventional methods. Absci's mission is to facilitate the development of improved medicines by effectively translating innovative ideas into viable drugs.

Lava Therapeutics B.V. is a biotechnology company based in Utrecht, the Netherlands, focused on innovative cancer treatments. Founded in 2016, it specializes in the development of proprietary bispecific antibodies that engage gamma-delta T cells, aiming to harness the immune system's power to target and destroy tumor cells. The company's platform creates next-generation γδ T cell engaging antibodies designed for both hematological and solid tumors, emphasizing safety, potency, and cost-effectiveness in its biopharmaceuticals. By combining immune recruiting and activating functionalities, Lava Therapeutics seeks to transform cancer therapy and improve patient outcomes.

Escient Pharmaceuticals, Inc. is a biotechnology company based in San Diego, California, specializing in the development and manufacture of G protein-coupled receptor (GPCR)-targeted drugs aimed at treating neuro-immuno-inflammatory and autoreactive diseases. Founded in 2017, Escient focuses on harnessing the therapeutic potential of specific orphan GPCRs, particularly the Mas-Related G-Protein Receptors (Mrgprs). The company aims to provide innovative therapies for a variety of conditions, including mast cell-mediated disorders and cholestatic pruritus, thereby expanding treatment options for healthcare providers facing these complex diseases.

Science 37, Inc. is a technology-enabled clinical trial company that specializes in developing patient-centric models for clinical research, aimed at accelerating biomedical discovery. The company utilizes its innovative platform, NORA (Network Oriented Research Assistant), a cloud-based mobile research tool that facilitates communication between researchers, patients, and mobile nurses through videos, surveys, and photographs. By providing decentralized clinical trial services, Science 37 enables access to diverse patient populations that traditional site-based research may overlook. The company has established itself as a leader in conducting virtual trials, leveraging an extensive network of telemedicine investigators and home-health nurses to enhance patient enrollment and retention. Serving a wide range of clients, including pharmaceutical sponsors, biotech firms, and academic institutions, Science 37 aims to transform clinical research through its comprehensive, fully integrated trial platform. Founded in 2014 and headquartered in Los Angeles, California, Science 37 continues to innovate in the field of clinical research.

Annexon Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapies for patients with classical complement-mediated disorders affecting the body, brain, and eye. The company's pipeline is built on a platform technology that targets well-researched autoimmune and neurodegenerative disease processes triggered by the aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon's lead product candidate, ANX005, is a full-length monoclonal antibody designed for intravenous administration to treat autoimmune and neurodegenerative disorders. Another key candidate, ANX007, is a monoclonal antibody Fab formulated for intravitreal administration to address neurodegenerative ophthalmic disorders. The company employs a biomarker-driven development strategy to ensure that its product candidates effectively engage the target at therapeutic doses within the intended patient tissue, while also exploring additional orphan and large market indications.

Shattuck Labs, Inc. is a clinical-stage biotechnology company based in Austin, Texas, focused on developing innovative therapeutics for cancer and autoimmune diseases. Founded in 2016, the company is advancing its proprietary Agonist Redirected Checkpoint (ARC) platform, which utilizes dual-function fusion proteins to enhance immune responses against tumors. Its lead product candidate, SL-172154, is currently undergoing Phase 1 clinical trials for ovarian cancer, aiming to inhibit the CD47/SIRPa checkpoint interaction while activating the CD40 receptor to restore and amplify anti-tumor immune responses. Additionally, Shattuck Labs is collaborating with Takeda Pharmaceuticals on SL-279252, which targets the PD-1/PD-L1 interaction and activates the OX40 receptor, and is also in Phase 1 trials for patients with advanced solid tumors and lymphoma. Through its innovative approach to immuno-oncology, Shattuck Labs seeks to address various cancer types and improve treatment options for patients.

Atea Pharmaceuticals is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on discovering and developing next-generation antiviral therapeutics for severe viral diseases. The company's lead candidate, AT-527, is an antiviral agent currently undergoing phase 3 clinical trials for the treatment of COVID-19, caused by the SARS-CoV-2 virus. Additionally, Atea is advancing several candidates in clinical trials, including AT-787 for hepatitis C and AT-752 for dengue, both in phase 2 trials. The company aims to provide innovative treatments for infections caused by RNA and DNA viruses, improving outcomes for patients suffering from serious viral infections. Atea Pharmaceuticals was incorporated in 2012.

Clear Labs, Inc. is a food analytics company based in Menlo Park, California, founded in 2013. The company specializes in providing a comprehensive food analytics platform that utilizes next-generation sequencing and data analytics to enhance food safety and quality control. Its offerings include Clear Dx™ and Clear Safety™, which facilitate the rapid identification of pathogens and support public health initiatives. Clear Labs' platform delivers critical insights into the molecular composition of foods and ingredients, testing for authenticity, contaminants, allergens, and other safety parameters. By offering transparency across supply chains, the company serves food manufacturers, suppliers, and retailers, enabling them to improve operational efficiency and safety through detailed analytics and reporting.

LifeSprout is developing the next generation of synthetic soft tissue substitutes for aesthetic and reconstructive medicine. They offer revolutionary products for aesthetic and regenerative medicine. They have created a platform that looks and behaves like the body’s own tissues. The company is turning this into a suite of products for millions of patients each year with soft tissue losses from aging, cancer, and metabolic disease.

Genalyte, Inc. is a clinical and diagnostic life sciences company based in San Diego, California, that specializes in rapid diagnostic testing solutions for healthcare providers, patients, and researchers. Founded in 2007, Genalyte has developed a unique technology platform employing silicon photonic biosensors to quantify the interactions between biomolecules, such as antibodies and proteins. This innovative approach allows for the direct measurement of protein binding and nucleic acid hybridization, facilitating the monitoring of autoimmune diseases, cancer biomarker screening, and the detection of infectious agents, including Ebola. The company's Maverick platform enables rapid testing in various healthcare settings, with results typically available in under thirty minutes, thereby enhancing patient care and improving resource efficiency within the healthcare system.

ElevateBio, LLC is a holding company based in Cambridge, Massachusetts, founded in 2017. It focuses on developing cell and gene therapies for the treatment of cancer and viral infections. The company operates a portfolio of subsidiaries that aim to manufacture and commercialize innovative medicines. ElevateBio collaborates with leading scientists and inventors to create a robust portfolio of therapeutic solutions. Additionally, it has established a centralized facility designed to streamline the translation of cell and gene therapy research into viable medical products, ensuring that patients have access to treatments for severe diseases in a timely manner.

immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors. immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.

Kymera Therapeutics, Inc. is a biopharmaceutical company based in Watertown, Massachusetts, specializing in targeted protein degradation. Founded in 2015, the company employs a proprietary platform that utilizes the body's natural protein degradation system to selectively degrade disease-causing proteins. Kymera is advancing several therapeutic programs, including its IRAK4 program aimed at treating immunology-inflammation diseases such as hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis. Additionally, it is developing the IRAKIMiD program for MYD88-mutated diffuse large B cell lymphoma and the STAT3 program targeting hematologic malignancies, solid tumors, and autoimmune diseases. By focusing on previously untreatable conditions and using innovative small molecule modalities, Kymera Therapeutics aims to revolutionize drug discovery and create effective treatments for challenging diseases.

Nurix Therapeutics is a biopharmaceutical company dedicated to the discovery, development, and commercialization of small molecule therapies aimed at modulating cellular protein levels for the treatment of cancer and immune disorders. The company has developed an integrated discovery platform known as DELigase, which leverages its expertise in E3 ligases—enzymes capable of modulating proteins within cells. Nurix's pipeline includes promising candidates such as NX-2127, an orally available Bruton’s tyrosine kinase degrader targeting relapsed or refractory B-cell malignancies, and NX-1607, an orally available inhibitor of Casitas B-lineage lymphoma proto-oncogene B, intended for immuno-oncology applications. Founded in 2009 and headquartered in San Francisco, California, Nurix Therapeutics was formerly known as Nurix Inc. and rebranded in October 2018. The company has established strategic collaborations with major industry players, enhancing its research and development capabilities.

Amunix Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to discovering and developing innovative protein and peptide therapeutics aimed at treating cancer. The company employs several proprietary platforms, including XTEN for extending drug half-life, XPAT for analyzing protease activity in the tumor microenvironment, and ProTIA, which focuses on immuno-oncology therapeutics. Amunix's product pipeline includes prodrugs and transformative T-cell engagers designed to activate the immune system against solid tumors. The company collaborates with various academic, biotechnology, and pharmaceutical sectors, maintaining strategic partnerships with organizations such as Janssen and Biogen-Idec. Founded in 2006 and headquartered in Mountain View, California, Amunix strives to deliver breakthroughs that can harness the immune system to combat cancer more effectively.

Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, dedicated to discovering and developing innovative therapies for fibrotic diseases. Its lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, targeting idiopathic pulmonary fibrosis and primary sclerosing cholangitis. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both indications and is currently undergoing Phase 2a clinical trials. The company is also developing PLN-1474, a small-molecule selective inhibitor of avß1, for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, which is in Phase 1 trials. Founded in 2015, Pliant Therapeutics is also advancing preclinical programs aimed at addressing oncology and muscular dystrophies.

Redx Pharma is a UK-based biotechnology company established in 2010, specializing in drug discovery and development with a focus on oncology and fibrotic diseases. The company aims to create innovative small molecule therapies addressing unmet medical needs, particularly in cancer and autoimmune disorders. Its product pipeline includes several drug candidates, such as RXC004, a porcupine inhibitor in Phase I clinical trials for various cancers; a ROCK inhibitor targeting inflammatory disease-related fibrosis; and a Pan-RAF inhibitor for colorectal cancer. Additionally, Redx Pharma is developing a ROCK2 inhibitor for diabetic nephropathy and idiopathic pulmonary fibrosis, as well as RXC005, a reversible Bruton’s tyrosine kinase inhibitor. The company also collaborates with Jazz Pharmaceuticals to explore cancer targets within the Ras/Raf/MAP kinase pathway. Redx Pharma operates through three subsidiaries focused on oncology, anti-infectives, and immunology, and generates revenue through scientific programs and research collaborations.

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in New York that focuses on developing small molecule therapeutics for cancer treatment. Established in 2014, the company employs an integrated discovery engine to identify and develop new chemical entities targeting critical biological pathways in various cancers. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader currently undergoing Phase I/II clinical trials for advanced or metastatic breast cancer. Additionally, Zentalis is advancing several other candidates, including ZN-c3, an inhibitor of the WEE1 protein for advanced solid tumors; ZN-d5, a selective inhibitor of B-cell lymphoma 2 for hematological malignancies; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor for advanced non-small cell lung cancer, all of which are in various stages of clinical development.

Repare Therapeutics Inc. is a precision oncology company based in Montréal, Canada, that specializes in discovering and developing targeted therapeutics through a synthetic lethality approach. Utilizing its proprietary SNIPRx platform, which integrates genome-wide analysis and CRISPR technology, Repare systematically identifies and advances cancer therapies aimed at genomic instability, particularly in DNA damage repair. The company's lead candidate, RP-3500, is an oral small molecule inhibitor designed for solid tumors with specific genomic alterations related to DNA damage repair. In addition, Repare is developing innovative programs such as a CCNE1-SL inhibitor for tumors with CCNE1 amplification and a Polymerase Theta program targeting BRCA mutations and other genomic changes. Founded in 2016, Repare Therapeutics is focused on addressing the unique vulnerabilities of tumor cells in genetically defined patient populations to enhance cancer treatment outcomes.

Achilles Therapeutics Ltd. is a biopharmaceutical company based in London, United Kingdom, specializing in the development of patient-specific immunotherapies designed to combat cancer. Founded in 2016, the company focuses on personalized vaccines and T cell therapies that utilize the body's immune system to target and eliminate cancer cells. Achilles Therapeutics aims to identify and target truncal tumor neoantigens and other markers present on cancer cells, allowing for precise attacks on tumors while sparing healthy tissue. The company is currently conducting clinical trials, including the CHIRON trial for non-small-cell lung cancer and the THETIS trial for recurrent or metastatic melanoma, to evaluate the efficacy and safety of its innovative therapies.

Stereotaxis, Inc. specializes in the design, manufacture, and marketing of robotic magnetic navigation systems aimed at enhancing the treatment of arrhythmias and coronary artery disease. Its core products include the Genesis and Niobe systems, which facilitate complex interventional procedures by enabling image-guided catheter and guidewire navigation within the heart. The company also offers the Vdrive system, which provides stability for diagnostic and therapeutic devices, and the Odyssey solution, a real-time information management system for interventional labs. Additionally, Stereotaxis produces various disposable components, such as automated catheter advancement devices, and collaborates with Osypka AG to develop next-generation magnetic ablation catheters. Founded in 1990 and headquartered in St. Louis, Missouri, Stereotaxis holds over 100 patents and markets its products through a combination of direct sales and partnerships with distributors and sales agents. The company's innovations aim to improve patient care through enhanced precision, safety, and efficiency in interventional procedures.

BioNTech is a Germany-based biotechnology company that specializes in developing innovative immunotherapies for cancer and other serious diseases, as well as vaccines for infectious diseases, including COVID-19. The company’s oncology pipeline includes a range of drug classes, such as mRNA-based drugs that encode antigens and neoantigens, cell therapies, bispecific antibodies, and antibody-drug conjugates. BioNTech has established partnerships with several major pharmaceutical companies, enhancing its research and development capabilities. Its COVID-19 vaccine, Comirnaty, represents its first commercialized product, demonstrating the company's commitment to addressing urgent health challenges through advanced therapeutic approaches.

IGM Biosciences, Inc. is a biotechnology company that specializes in the research and development of engineered Immunoglobulin M (IgM) antibodies aimed at treating cancer and other diseases. The company’s lead product candidate, IGM-2323, is a bispecific IgM antibody currently undergoing Phase 1 clinical trials for the treatment of relapsed or refractory B cell Non-Hodgkin's lymphoma. In addition, IGM is developing IGM-8444, an IgM antibody targeting Death Receptor 5 for solid and hematologic malignancies, and IGM-7354, a bispecific IgM antibody designed to deliver interleukin-15 cytokines to PD-L1 expressing cells. IGM Biosciences has established collaborations focused on the discovery and development of novel IgM and IgA antibodies, including partnerships for potential COVID-19 treatments. Founded in 1993 and headquartered in Mountain View, California, the company was previously known as Palingen, Inc. and adopted its current name in 2010.

ADC Therapeutics SA is a clinical-stage biotechnology company based in Epalinges, Switzerland, specializing in the development of antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. The company's lead product candidates include ADCT-402, currently undergoing a Phase II clinical trial for relapsed or refractory diffuse large B-cell lymphoma, and ADCT-301, which is in a pivotal Phase II trial for relapsed or refractory Hodgkin lymphoma, non-Hodgkin lymphoma, and solid tumors. ADC Therapeutics employs advanced pyrrolobenzodiazepine (PBD) dimer technology to create highly potent and targeted ADCs, which demonstrate a superior therapeutic index compared to earlier generation products. In addition to its lead candidates, the company is developing several clinical-stage and preclinical product candidates, including ADCT-601, ADCT-602, ADCT-701, and ADCT-901. ADC Therapeutics also collaborates with Genmab A/S to enhance its development efforts. The company was incorporated in 2011.

AlloVir, Inc. is a clinical-stage cell therapy company based in Cambridge, Massachusetts, specializing in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies aimed at preventing and treating serious viral-associated diseases. The company's lead product, Viralym-M, targets multiple viruses including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. Additionally, AlloVir is advancing several product candidates through preclinical and clinical stages, such as ALVR106 for respiratory syncytial virus and influenza, ALVR109 for SARS-CoV-2, ALVR107 for hepatitis B, and ALVR108 for human herpesvirus-8. The company, originally founded in 2013 as ViraCyte, Inc., rebranded to AlloVir in May 2019 and is committed to addressing the urgent medical needs of patients with limited treatment options for viral diseases.